Product Data Sheet

CBP/p300-IN-3

Cat. No.: HY-128876 CAS No.: 2299226-01-8 Molecular Formula: $C_{24}H_{29}N_7O$ Molecular Weight: 431.53

Target: Histone Acetyltransferase

Pathway: **Epigenetics**

Storage: Powder -20°C 3 years

2 years

In solvent -80°C 2 years

> -20°C 1 year

SOLVENT & SOLUBILITY

In Vitro

DMSO: 250 mg/mL (579.33 mM; Need ultrasonic)

Preparing Stock Solutions	Solvent Mass Concentration	1 mg	5 mg	10 mg
	1 mM	2.3173 mL	11.5867 mL	23.1734 mL
	5 mM	0.4635 mL	2.3173 mL	4.6347 mL
	10 mM	0.2317 mL	1.1587 mL	2.3173 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

- 1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 2.08 mg/mL (4.82 mM); Clear solution
- 2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: ≥ 2.08 mg/mL (4.82 mM); Clear solution
- 3. Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 2.08 mg/mL (4.82 mM); Clear solution

BIOLOGICAL ACTIVITY

Description

CBP/p300-IN-3, a p300/CBP histone acetyltransferase inhibitor, Compound 6, is sourced from patent WO 2019049061 A1^[1].

REFERENCES

[1]. Medina, et al. 5-(1H-Benzo[d]imidazol-2-yl)pyridin-2-amine and 5-(3H-imidazo[4,5-b]pyridin-6-yl)pyridin-2-amine derivatives as c-MYC and p300/CBP histone

cetyltransferase inhibitors for treating cancer and their preparation.							
	Continue Booth of the continue of		distanting the state of the sta				
			dical applications. For research use only				
	Tel: 609-228-6898 Address: 1	Fax: 609-228-5909 Deer Park Dr, Suite Q, Monmo	E-mail: tech@MedChemExpress.com uth Junction, NJ 08852, USA				

Page 2 of 2 www.MedChemExpress.com